Exclusive Summary

• Zero IP risk with rigid demand: With expired original patents, it acts as the first-line specific antidote for benzodiazepine overdose and an essential agent for post-anesthesia reversal in ERs and ICUs globally.
• Full spectrum of specifications: Offering 2ml(0.2mg), 5ml(0.5mg), and 10ml(1.0mg) covers all clinical dosage requirements, empowering distributors with a competitive edge in hospital and public procurement bids.
• High profit margins with ready-to-register support: Leveraging China's manufacturing cost efficiencies and complete CTD dossiers to help distribution partners achieve fast local registration and maximize their commercial margins.